Micro Interventional Devices, Inc.

Micro Interventional Devices, Inc. Wins CRT 2017’s “Top Cardiovascular Innovation Award” for MIA(TM), Minimally Invasive Annuloplasty Technology

World’s first annuloplasty system for mitral and tricuspid repair incorporating proprietary PolyCor(TM) and MyoLast(TM) technologies.

Newtown, PA – March 2, 2017Micro Interventional Devices, Inc™ (MID), is pleased to announce that it is the recipient of the CRT 2017 “Top Cardiovascular Innovation Award” for the company’s MIA technology. The award was presented to Michael Whitman, MID’s Founder, President and CEO, during the 20th annual CRT meeting on Tuesday, February 21st.

“Receiving the 2017 ‘Top Cardiovascular Innovation Award’ at one of the world’s leading interventional cardiology conferences is an honor,” said Michael Whitman. “The promising early data from our STTAR Study in the EU indicates that our MIA technology is effective in reducing annular dimensions and tricuspid regurgitation. CRT’s recognition of the encouraging clinical results and the potential for MIA to provide an effective percutaneous solution for the treatment of tricuspid and mitral valve disease is a tremendous accomplishment for our team.”

The MIA technology is designed to reduce annular dimensions and regurgitation during percutaneous transcatheter mitral and tricuspid repair. The annular reduction is achieved without sutures or other intervention due to the compliant, self-tensioning MIA implant incorporating the company’s proprietary PolyCorTM anchors and MyoLastTM implantable elastomer.

About Micro Interventional Devices, Inc. (MID):

MID is the world leader in percutaneous transcatheter compliant fixation technology addressing unmet needs in structural heart disease.

Saladax Licenses Alzheimer’s Diagnostic Tests to Siemens Healthineers

Tests can lead to early identification of Alzheimer’s Disease

Bethlehem, PA–(BUSINESS WIRE)–January 18, 2017– Saladax Biomedical, Inc., a privately held company focused on precision in-vitro diagnostic tests, announced today that it has signed an agreement to license diagnostic tests for Alzheimer’s disease (AD) to Siemens Healthineers. Saladax’s tests identify the amyloid beta 1-42 and tau biomarkers in cerebrospinal fluid (CSF) which are known and accepted biomarkers for AD.

Alzheimer’s Disease is currently the sixth leading cause of death in the U.S., affecting nearly 50 million patients worldwide, with 10 million new cases each year.  Presently, no disease-modifying therapeutics exist, and the available drugs provide limited alleviation of symptoms.  The use of tests to identify CSF biomarkers much sooner than previously available, will give clinicians the ability to more accurately identify AD and begin treatment sooner. Early detection of AD is also an important step in better understanding the disease.

The two biomarkers have been extensively studied for over 20 years, and are key indicators of the early stages of Alzheimer’s disease.  Currently, evidence of early AD can only be determined by PET (positron emission tomography) imaging equipment such as can be found with Siemen’s PETNET Solutions, or biomarkers such as Saladax’s amyloid beta 1-42 and tau tests.

“We are very excited to be working with Siemens Healthineers to bring these important assays to the market,” said Sal Salamone, Ph.D., CEO of Saladax Biomedical, Inc.  “Siemens is an ideal partner with a strong global position and high quality instrumentation.”

Under this non-exclusive agreement, Saladax will provide its proprietary raw materials, protocols, and intellectual property and Siemens will be responsible for the commercialization of both assays.

About Saladax Biomedical, Inc.
Saladax Biomedical is a leader in the development and deployment of high-quality diagnostic services and products to help physicians select and optimize the use of current and new pharmaceutical products, to improve treatment and positively impact the economics of care… because no two patients are alike.

Headquartered in Bethlehem, Pennsylvania, Saladax was founded in 2004 and is ISO 13485:2003 certified. For more information visit: www.saladax.com

Company draws on capital connections

Stephanie Reisinger has worked in Harrisburg’s science and tech sector for over 16 years. In that time, she has experienced firsthand the benefits that the area can offer science and tech-focused companies.

The above article appeared in the October 28, 2016 edition of the Central Penn Business Journal to continue reading click here:    http://www.cpbj.com/article/20161031/CPBJ01/161039968/company-draws-on-capital-connections


Often when one thinks of the life sciencesA cluster of scientific disciplines concerned with human life and health. Included are many branches of biology (e.g., molecular biology, cell biology) and chemistry (e.g., biochemistry), as well as some areas of genetics, physics and materials science, among others. industry, the larger metropolitan areas with sizeable research centers such as Boston and Philadelphia and Washington, DC are the first to come to mind.  However, …

This article was published in the 2016 Fall Edition of HRN HARRISBURG REGIONAL NEWS to continue reading click here:  http://knowthisplace.com/pa/harrisburg-regional-news-fall-2016/ .  The article is on page 12.

Micro Interventional Devices, Inc. Receives FDA Market Clearance for Permaseal™

INDIGO Biosciences Raises $500 Thousand in Series B Funding

Micro Interventional Devices, Inc. Receives CE Mark Approval for Permaseal

Micro Interventional Devices, Inc. Receives CE Mark Approval for PermasealTM

Disruptive technology simplifies minimally invasive cardiovascular surgery. Newtown, PA – June 7, 2016 – Micro Interventional Devices, Inc.™ (MID), the world leader in minimally invasive and catheter-based compliant fixation technology announced today that it received CE Mark approval for the Company’s first product: Permaseal™ transapical access and closure device.  The Permaseal device allows surgeons to access and close the left-ventricle instantaneously, reliably and without suturing the myocardium. Permaseal is the world’s first device using compliant soft-tissue PolyCorTM anchor technology.

Permaseal was validated in the STASIS Clinical Study (Secure Transapical Access and Closure Study) conducted at five European Sites. Results indicated  that Permaseal shortened operating time and hospital stay, reduced adverse events including the need for transfusion and reduced 12-month mortality and stroke rates to 0%*. The technology provides a direct, safe and simple, access and closure site for emerging complex structural heart disease procedures including TAVR, TMVR, PFO, and other minimally invasive cardiac procedures.

“The CE Mark approval of Permaseal is a tremendous achievement for MID,” said Michael Whitman, MID’s Founder, President & CEO. “Permaseal is the first in a series of products designed to replace the need for suturing in structural heart procedures. We are excited that this technology is now available to our European surgeons and their patients.”

“In the near future, PolyCor and MyoLastTM technologies will be utilized in a broad range of proprietary, catheter-based products, addressing unmet needs in tricuspid repair, mitral repair and mitral valve fixation,” added Whitman. “MID’s technology platform enables open-surgical procedures to be performed percutaneously.”

Permaseal is currently the only transapical access and closure device available for commercial use in the EU. FDA clearance to market Permaseal is pending.

*Data on file.

About Micro Interventional Devices, Inc. (MID):
MID is the world leader in compliant fixation technology addressing unmet needs in structural heart disease.

Company Contact:
Micro Interventional Devices, Inc.
Katherine Whitman
Product Director
215 600 1270

Here’s how to keep Pa’s medical innovation ecosystem healthy: Mel Billingsley

Researchers at Penn State’s Hershey Medical Center’s Division of Artificial Organs are at work testing heart-assist devices for adults and children.

This long-standing, successful program aims    –   this op-ed appeared on PennLive on May 11, 2016.  To continue reading click here: http://www.pennlive.com/opinion/2016/05/heres_how_to_keep_pas_medical.html#incart_river_index



Managing macular degeneration

When it comes to vision loss, macular degeneration poses the biggest threat.

People pay attention to cataracts, glaucoma and diabetic retinopathy…..

This article by Matthew Jojiri was published in the January 19, 2016 edition of the Reading Eagle.  Click here to continue reading:  http://www.readingeagle.com/life/article/managing-macular-degeneration&template=mobileart

Health care IT firm bolsters tech-related growth in downtown Harrisburg

It’s a lot like getting the band back together for a road trip.

That’s the way Mel Billingsley, president and CEO of the Harrisburg-based Life Sciences Greenhouse of Central Pennsylvania, describes a recent move by Maryland-based Evidera to open in the greenhouse’s building at 225 Market St.

This article appeared in the December 4th edition of the Central Penn Business Journal.  To continue reading click here:  http://www.cpbj.com/article/20151204/CPBJ01/151209880/health-care-it-firm-bolsters-techrelated-growth-in-downtown-harrisburg?utm_source=CPBJ%20Evening%20Rush&utm_medium=Email&utm_term=http%3a%2f%2fwww.cpbj.com%2farticle%2f20151204%2fCPBJ01%2f151209880%2fhealth-care-it-firm-bolsters-techrelated-growth-in-downtown-harrisburg&utm_campaign=Health%20care%20IT%20firm%20bolsters%20tech-related%20growth%20in%20downtown%20Harrisburg

  • The Funding Process

    The Funding Process

    The Life Sciences Greenhouse of Central Pennsylvania provides investment funding up to $1 million in milestone-driven convertible…

    Read more
  • Our Resource Center


    It’s a familiar scenario. You hear about a discovery that could lead to the cure for this disease or that debilitating…

    Read more
  • The 'PA' in LSGPA


    The Life Sciences Greenhouse of Central Pennsylvania’s 42-county service area contains more than 60 institutions of higher …

    Read more